{"id":76762,"date":"2026-08-27T12:21:08","date_gmt":"2026-08-27T04:21:08","guid":{"rendered":"https:\/\/flcube.com\/?p=76762"},"modified":"2026-08-27T12:21:09","modified_gmt":"2026-08-27T04:21:09","slug":"fda-approves-revolution-medicines-rasonque-daraxonrasib-an-oral-multi-selective-rason-inhibitor-for-metastatic-pancreatic-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=76762","title":{"rendered":"FDA Approves Revolution Medicines’ Rasonque (daraxonrasib), an Oral Multi\u2011Selective RAS(ON) Inhibitor, for Metastatic Pancreatic Cancer"},"content":{"rendered":"\n

The U.S. Food and Drug Administration (FDA)<\/strong> has approved Revolution Medicines’<\/strong> Rasonque (daraxonrasib)<\/strong> for the treatment of adult patients with metastatic pancreatic adenocarcinoma (PDAC)<\/strong> who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. The approval marks a significant regulatory milestone for a therapy designed to target cancers driven by a broad range of common RAS<\/strong> genotypes, addressing a disease long considered among the most difficult to treat in oncology.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/td>U.S. Food and Drug Administration (FDA)<\/td><\/tr>
Approval Type<\/td>Marketing approval<\/td><\/tr>
Product<\/td>Rasonque (daraxonrasib)<\/strong><\/td><\/tr>
Indication<\/td>Adult patients with metastatic pancreatic adenocarcinoma (PDAC) who have received \u22651 prior systemic therapy or are not candidates for multiagent systemic therapy<\/td><\/tr>
Approval Date<\/td>26 Aug 2026<\/td><\/tr>
Next Steps<\/td>Global Phase 3 registrational programs ongoing in PDAC and metastatic RAS\u2011mutant NSCLC<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Mechanism of Action<\/h2>\n\n\n\n